![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/GUFICBIO.png)
Share the post "Gufic Biosciences ‘s Q3 2024-25 Latest News: Revenue Rises by 2.98% YoY"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 2.98 % in the past year, substantial increase in net sales/revenue by 1.77 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 339.62 %. Marginal increase in other income during this quarter, up by 1535.09%. 🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Gufic Biosciences Limited. Profit dropped by -13.18 % Year to Year, Gufic Biosciences Limited’s profitability dropped by -11.26 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS declined by -13.45 % Year to Year. EPS decreased by -11.06 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 201.778 Cr | Rs. 204.18 Cr | Rs. 207.794 Cr | + 1.77 % | + 2.98 % |
| Expenses | Rs. 165.32 Cr | Rs. 165.55 Cr | Rs. 173.85 Cr | + 5.01 % | + 5.16 % |
| Operating Profit | Rs. 36.46 Cr | Rs. 38.63 Cr | Rs. 33.94 Cr | -12.14 % | -6.91 % |
| OPM % | 18.07 % | 18.92 % | 16.33 % | -2.59 % | -1.74 % |
| Other Income | Rs. 0.424 Cr | Rs. 0.114 Cr | Rs. 1.864 Cr | + 1535.09 % | + 339.62 % |
| Interest | Rs. 3.18 Cr | Rs. 5.18 Cr | Rs. 4.91 Cr | -5.21 % | + 54.4 % |
| Depreciation | Rs. 4.14 Cr | Rs. 4.3 Cr | Rs. 4.62 Cr | + 7.44 % | + 11.59 % |
| Profit before tax | Rs. 29.56 Cr | Rs. 29.26 Cr | Rs. 26.27 Cr | -10.22 % | -11.13 % |
| Tax % | 24.7 % | 25.58 % | 26.46 % | + 0.88 % | + 1.76 % |
| Net Profit | Rs. 22.26 Cr | Rs. 21.78 Cr | Rs. 19.32 Cr | -11.29 % | -13.21 % |
| EPS in Rs | Rs. 2.23 | Rs. 2.17 | Rs. 1.93 | -11.06 % | -13.45 % |
Today, we’re looking at Gufic Biosciences Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 2.98 %. However, it did see a marginal increase of 1.77 % from the previous quarter. Expenses ticked up slightly by 5.01 % quarter-on-quarter, aligning with the annual rise of 5.16 %. Operating profit, while down -6.91 % compared to last year, faced a quarter-on-quarter dip of -12.14 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -1.74 %, but a shrinkage of -2.59 % sequentially. Other income rose by 1535.09 % compared to the last quarter, despite an annual growth of 339.62 %. Interest expenses dropped significantly by -5.21 % from the previous quarter, yet the year-over-year increase remains at a moderate 54.4 %. Depreciation costs climbed by 7.44 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 11.59 %. Profit before tax declined annually by -11.13 % but saw a reduction from the preceding quarter by -10.22 %.
Tax expenses as a percentage of profits increased slightly by 1.76 % compared to last year, with a more notable quarter-on-quarter increase of 0.88 %. Net profit fell by -13.21 % year-on-year but witnessed a -11.29 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -13.45 % but a quarterly fall of -11.06 %. In summary, Gufic Biosciences Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 201.778 Cr | Rs. 204.18 Cr | Rs. 207.794 Cr | + 1.77 % | + 2.98 % |
| Expenses | Rs. 165.32 Cr | Rs. 165.55 Cr | Rs. 173.85 Cr | + 5.01 % | + 5.16 % |
| Operating Profit | Rs. 36.46 Cr | Rs. 38.63 Cr | Rs. 33.94 Cr | -12.14 % | -6.91 % |
| Net Profit | Rs. 22.26 Cr | Rs. 21.78 Cr | Rs. 19.32 Cr | -11.29 % | -13.21 % |
| EPS in Rs | Rs. 2.23 | Rs. 2.17 | Rs. 1.93 | -11.06 % | -13.45 % |
In reviewing Gufic Biosciences Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 2.98 % year-on-year growth, however, there was a minor increase of 1.77 % from the previous quarter. Expenses rose by 5.16 % compared to the previous year, with a 5.01 % increase quarter-on-quarter. Operating Profit dropped by -6.91 % annually, and saw a -12.14 % decrease from the last quarter.
Net Profit showed yearly decrease of -13.21 %, and experienced a -11.29 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -13.45 % annually, however dipped by -11.06 % compared to the last quarter. In essence, while Gufic Biosciences Limited faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
 Ltd. logo1.jpg){kind=logo}